chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Sickness; Tachycardia; Pain; Dizziness; Fever; Chills; a lot of muscle pain after the second dose of the vaccine; Arthralgia; This spontaneous case was reported by a pharmacist and describes the occurrence of ILLNESS (Sickness), TACHYCARDIA (Tachycardia), PAIN (Pain), DIZZINESS (Dizziness) and PYREXIA (Fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ILLNESS (Sickness), TACHYCARDIA (Tachycardia), PAIN (Pain), DIZZINESS (Dizziness), PYREXIA (Fever), CHILLS (Chills), MYALGIA (a lot of muscle pain after the second dose of the vaccine) and ARTHRALGIA (Arthralgia). At the time of the report, ILLNESS (Sickness), TACHYCARDIA (Tachycardia), PAIN (Pain), DIZZINESS (Dizziness), PYREXIA (Fever), CHILLS (Chills), MYALGIA (a lot of muscle pain after the second dose of the vaccine) and ARTHRALGIA (Arthralgia) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication reported. No treatment medication reported.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 18-Aug-2021: Follow-up received on 18 Aug 2021, Added events.
HIGH HEART BEAT; SICK IN THE STOMACH; FEVER; This spontaneous report received from a patient concerned a 69 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805025, expiry: UNKNOWN) dose was not reported, administered on 16-MAR-2021 on left arm for prophylactic vaccination. No concomitant medications were reported.  On 16-MAR-2021 15:00, the subject experienced fever. On an unspecified date, the subject experienced high heart beat, and sick in the stomach. Laboratory data (dates unspecified) included: Heart rate (NR: not provided) HIGH. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from fever, and the outcome of high heart beat and sick in the stomach was not reported. This report was non-serious.
Noted small red healed area on left lateral thigh approx. size small eraser. No noted signs of severe distress. Child alert playful walking on legs with no trouble. Parents understand need to follow up with Pvt. MD or ER if any other problems occur. Parent given my business card.
Vaccines were given, patient went to waiting room and within a few minutes he came back with hives on face & trunk. Hives pruritic. Moderate hives. 9ml BENADRYL given by mouth.
one dose was given after excursion of 8 hours and 41 minutes at 8.2 degrees.; Case reference number US-BN-2021-000136 is a spontaneous case report initially received from nurse via Agency (case reference number USBAV21-0082) on 02-Mar-2021, and concerns a 57-year-old male patient.  The patient's medical history and concomitant medication details were not provided.  On unspecified date (one week before the second vaccination, as stated by the reporter), the patient received the first dose of RabAvert (Inactivated Rabies Virus Vaccine, Batch no. was not provided) at unknown dosage regimen (one injection reported), administrated intramuscularly and for pre-exposure prophylaxis.   On 01-Mar-2021, the patient was administrated the second dose of RabAvert (Inactivated Rabies Virus Vaccine, Batch no. was not provided) at unknown dosage regimen, administrated intramuscularly and for pre-exposure prophylaxis.  It was stated by the reporter that the vaccine had a temperature excursion of 8 hours and 41 minutes at 8.2 degrees (unit was not specified), and that regardless of the event (Product temperature excursion issue) patient received second vaccine dose.  At the time of this report outcome of this event remains unknown.  It was not reported did the patient experienced any adverse effect due to RabAvert.  No further information was provided.  Company comment: Product temperature excursion issue is listed by convention. Reportedly, the patient received the second dose of RabAvert after the product had been stored at a temperature excursion at 8.2 degrees, that is considered to be product temperature excursion issue. The event is not related to the suspect product but to human action.; Reporter's Comments: Product temperature excursion issue is listed by convention. Reportedly, the patient received the second dose of RabAvert after the product had been stored at a temperature excursion at 8.2 degrees, that is considered to be product temperature excursion issue. The event is not related to the suspect product but to human action.; Sender's Comments: Product temperature excursion issue is listed by convention. Reportedly, the patient received the second dose of RabAvert after the product had been stored at a temperature excursion at 8.2 degrees, that is considered to be product temperature excursion issue. The event is not related to the suspect product but to human action.
Within 1-2 minutes of taking the vaccine , I started having shortness of breath,  my heart rate was rapid,  severe chest tightness, and dizziness , tingling in the whole body , face became pale and flushed .
This case was reported by a consumer and described the occurrence of influenza in an adult female subject who was vaccinated with influenza virus vaccine (Fluarix, GlaxoSmithKline) for prophylaxis. A physician or other health care professional has not verified this report. On an unspecified date the subject received unspecified dose of Fluarix (unknown). At an unspecified time after vaccination with Fluarix, in February 2008, the subject experienced influenza and vaccination failure. At an unspecified time after vaccination with Fluarix and on a unspecified date, the subject experienced cough. This case was assessed as medically serious by GSK. The subject was treated with oseltamivir phosphate (TAMIFLU). At the time of reporting the event of influenza was improved, but the subject still had a cough.
Chilling; lowgrade fever 100.9; Extreme nausea; body ache; This spontaneous case was reported by a nurse and describes the occurrence of FEELING COLD (Chilling), PYREXIA (lowgrade fever 100.9), NAUSEA (Extreme nausea) and MYALGIA (body ache) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 007M20A and 039K20A) for COVID-19 prophylaxis.     The patient's past medical history included Stevens-Johnson syndrome and Breast cancer (removal and repair in 2013). Concurrent medical conditions included Penicillin allergy (Penicillin reaction: Stevens-Johnson syndrome), Drug allergy (Keflex reaction: Stevens-Johnson syndrome) and Irritable bowel syndrome. Concomitant products included VITAMINS NOS, FISH OIL, POLYCARBOPHIL CALCIUM (FIBER), CALCIUM, DOCUSATE SODIUM (STOOL SOFTENER) and XYLOMETAZOLINE HYDROCHLORIDE (SUDAFED [XYLOMETAZOLINE HYDROCHLORIDE]) for an unknown indication.   On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FEELING COLD (Chilling), PYREXIA (lowgrade fever 100.9), NAUSEA (Extreme nausea) and MYALGIA (body ache). At the time of the report, FEELING COLD (Chilling), PYREXIA (lowgrade fever 100.9), NAUSEA (Extreme nausea) and MYALGIA (body ache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Pyrexia: 100.9 100.9.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient never had COVID test or diagnosis. Patient never had reaction to taking the Flu shot. Reporter reporting side effects after Moderna vaccine stated that side effects got worse with every vaccine. No treatment medications was provided.   This case was linked to MOD-2022-588873, MOD-2022-589013, MOD-2022-589045 (Patient Link).
SEVERE MIGRAINE/MIGRAINE HEADACHE; DIZZINESS; LIGHT HEADEDNESS; THROBBING PAIN; INJECTION SITE PAIN; NAUSEA; This spontaneous report received from a patient concerned a 47 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included migraine, seasonal allergy, and seafood allergy. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 041A21A, expiry: UNKNOWN) dose was not reported, administered on 02-APR-2021 for prophylactic vaccination. Concomitant medications included botulinum toxin type a for migraine. On APR-2021, Laboratory data included: Blood test (NR: not provided) UNKNOWN, MRI brain (NR: not provided) UNKNOWN, and Nuclear magnetic resonance angiography brain (NR: not provided) UNKNOWN. On 03-APR-2021, the subject experienced severe migraine/migraine headache. On 03-APR-2021, the subject experienced dizziness. On 03-APR-2021, the subject experienced light headedness. On 03-APR-2021, the subject experienced throbbing pain. On 03-APR-2021, the subject experienced injection site pain. On 03-APR-2021, the subject experienced nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from severe migraine/migraine headache, had not recovered from dizziness, light headedness, throbbing pain, and nausea, and the outcome of injection site pain was not reported. This report was non-serious.
tested positive today for Covid; This is a spontaneous report from a contactable consumer. This (age: 37; unit: unknown) male consumer (patient) received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on 17Mar2021 at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. Eight days later, on 24-Mar-2021 the patient tested positive for Covid and wanted to know if that was the reason for which Pfizer called him. He wanted to know the dosing intervals between the first and second dose of the Pfizer BioNTech Covid vaccine and if he could still get his second dose as planned because he got Covid between doses one and two. The patient had some symptoms, so he went and got tested and experienced loss of taste of smell, congestion and slight cough. The outcome of events was unknown.  Information about lot/batch number has been requested.
Over the course of 4 weeks after my second shot, I experienced the following symptoms which came and went and were present on my body in different locations throughout the four weeks. Skin sensitivity to the touch which felt like bad razor burn concentrated on the left side of my body - the outside edge of my left foot and up the outside of my left leg. Also, present on the back of my upper left and right legs, upper left hip and waist area. For about 2 days (14 days after the shot) both feet felt as though they were burning, toes were extremely sensitive to the touch, it was uncomfortable to use a towel to dry them off after a shower. Other adverse events included prolonged exhaustion throughout the 4 weeks and joint pain for approximately 2 weeks after the second dose. The longest lasting side effects were the exhaustion and skin sensitivity.
Fever; Fatigue; This case was reported by a physician via call center representative and described the occurrence of fever in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced fever and fatigue. On an unknown date, the outcome of the fever and fatigue were unknown.   It was unknown if the reporter considered the fever and fatigue to be related to Shingrix.     Additional Information: GSK Receipt Date: 13-Jul-2022. Reporter's Comments: Physician had a question that how soon after receiving Shingrix vaccine does a patient develop fever and fatigue does that take 24 hours or they could develop sooner in first few hours? Physician was tried to figure out if it was the vaccine or something else. The reporter did not consent to follow up. No other details available.
We stayed at the clinic for 15 minutes.  About 10 minutes after we were released, I felt my tongue start to feel thick, then my throat felt like it was swelling and I became short of breath.  Also it progressed to my lips feeling numb.  My voice wasn't normal sounding to my husband.  We had gone to the clinic with another couple who drove and I chose not to let them know about my symptoms unless they continued to progress, which they did not.  The symptoms persisted for about 90 minutes.  By the time we got home, the symptoms had pretty much resolved, but I took a Benadryl 25mg anyway.
hard for her to swallow food; discomfort in her thyroid; when bending her neck it gives pain in her neck; her vision has gotten worst; mouth is dry; needs to drink more water.; Has headaches that she has never had before; This spontaneous case was reported by a consumer and describes the occurrence of DYSPHAGIA (hard for her to swallow food), THYROID DISORDER (discomfort in her thyroid), NECK PAIN (when bending her neck it gives pain in her neck), VISUAL IMPAIRMENT (her vision has gotten worst) and DRY MOUTH (mouth is dry) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included ALPRAZOLAM (XANAX) for Anxiety, PARACETAMOL (TYLENOL) for Pain, PRAVASTATIN for Triglycerides high, LANSOPRAZOLE (PREVACID) and LURASIDONE HYDROCHLORIDE (LATUDA) for an unknown indication.    On 13-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DYSPHAGIA (hard for her to swallow food), THYROID DISORDER (discomfort in her thyroid), NECK PAIN (when bending her neck it gives pain in her neck), VISUAL IMPAIRMENT (her vision has gotten worst), DRY MOUTH (mouth is dry), DEHYDRATION (needs to drink more water.) and HEADACHE (Has headaches that she has never had before). At the time of the report, DYSPHAGIA (hard for her to swallow food), THYROID DISORDER (discomfort in her thyroid), NECK PAIN (when bending her neck it gives pain in her neck), VISUAL IMPAIRMENT (her vision has gotten worst), DRY MOUTH (mouth is dry), DEHYDRATION (needs to drink more water.) and HEADACHE (Has headaches that she has never had before) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Past medical history includes past medical problem with esophagus, Gerd issues, that seems to getting worst from what was before with unknown date.  Events include has some fracture disk and vertebrae problem that has gotten worst with unknown date and unknown outcome.    Concomitant medications includes 2 other medicine for depression with unknown date.  No treatment information was provided.
pt recvd vax;devel a target like rash on leg & foot;test pos for central necrosis in target lesions prompting dx of erythema multiforme;lab test:hemoglobin 11g/dl,AST 39 IU/L;tx w/ ibuprofen;
Given only the grey vial; Given only the grey vial; This case was reported by a nurse via sales rep and described the occurrence of inappropriate preparation of medication in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.  Additional details provided were as follows: The age at vaccination was not reported. The patient received only the grey vial of Menveo which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter consented to follow-up.
Vasovagal reaction and vomiting.  Blood pressure 102/60 at 1046; 97/66 at 1110; 95/71 at 1116.   Pt given orange juice. Refused to go to the ER.  Once stable, Family member was contacted and took pt home
Receiving Moderna COVID-19 vaccine as a second dose but already received Pfizer COVID-19 vaccine as a 1st dose; This spontaneous case was reported by a nurse and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Receiving Moderna COVID-19 vaccine as a second dose but already received Pfizer COVID-19 vaccine as a 1st dose) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014F21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    Concurrent medical conditions included Anxiety. Concomitant products included TRAZODONE, PAROXETINE and BUSPIRONE for an unknown indication.   On 27-Jul-2021, the patient started TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 16-Sep-2021 at 3:45 PM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Sep-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Receiving Moderna COVID-19 vaccine as a second dose but already received Pfizer COVID-19 vaccine as a 1st dose). On 16-Sep-2021, INTERCHANGE OF VACCINE PRODUCTS (Receiving Moderna COVID-19 vaccine as a second dose but already received Pfizer COVID-19 vaccine as a 1st dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 20-Sep-2021: Follow-up was received on 20-SEP-2021 and Patient's demographics added, race and ethnicity added, medical history added, concomitant medication dosage details and frequency added
Information has been received from a consumer concerning her 12 month old son who on 04/16/01 was vaccinated with MMRII. It is unknown if other vaccines were administered on that day. On 04/21/01. the patient experienced a rash on his forehead and ears. It was describes as bumpy white dots that became red and then formed red dots. The rash later spread to his stomach. The child was seen by a doctor on 04/26/01 who thought it was vaccine related with slighty swollen glands. The child was seen by a dermatologist on 04/27/01 who thought it was a "morbilliform rash".  The dermatologist applied an unnamed corticosteroid" to the rash. On 04/29/01, the patient had a fever and, as of, 04/30/01, the fever continued and the glands were more swollen. Additional information has been requested.
Localized rash on upper lft thigh & erythema spreading to max of 3" x 4" with small area of fine rash & dense tissue.
patient reported on 05/07/23 regarding red rash around injection site. no other symptoms were present at this time. advised patient that we will follow up in a day or two, to monitor for improvement/worsening of the rash. was informed by patient that the rash developed into an infection on 5/8/23. patient was treated for a skin infection with cephalexin 500mg, 1 capsule by mouth every 8 hours for 7 days
Inappropriate Age; Wrong vaccine administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 21-year-old female patient who received DTPa (Infanrix) (batch number Y42F9, expiry date 03-MAR-2024) for prophylaxis.   On 03-JUL-2023, the patient received Infanrix. On 03-JUL-2023, an unknown time after receiving Infanrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Inappropriate Age) and wrong vaccine administered (Verbatim: Wrong vaccine administered). The outcome of the inappropriate age at vaccine administration and wrong vaccine administered were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 03-JUL-2023 The reporter was a medical assistant. The reporter called to inquire that how to proceed with series and what to look for in the patient or any side effects. The reporter mentioned that the Boostrix dose would have been a second Tdap for the patient. The reporter consented to follow up. The reporter reported that Infanrix dose was administered to a 21 year old patient at the time of reporting, when the patient was ordered to receive a Boostrix dose, which led to wrong vaccine administered and inappropriate age at vaccine administration.
Severe headache, back and muscle pain never go away since vacinnated. Thought was the normal symptoms last just  for a few weeks but still suffering now.
1.  Intense bloody nose that bled for 35 minutes, very heavy flow and had a hard time stopping it. 2.  Menstrual cycle started 13 days early with unusually heavy flow and cramping.
Tested positive for COVID-19 on July 26, 3 months after the 2nd shot
Pt had a rash and red bump at the injection site.She has a diffuse maculopapular rash starting 6 hours after Hep B, PCV13, DTAP-Hib-IPV She is afebrile and rash is not targetoid, so not likely serum sickness. NO joint swelling. No hand swelling.  She is slightly fussy We discuss monitoring for mucus membrane involvement  VAERS completed  Will rx topical steroid for comfort as she seems uncomfortable
Patient experienced vagal reaction to the vaccine. He states that this is due to the fear of needles.
arm hurt; tired; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (tired) and PAIN IN EXTREMITY (arm hurt) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 26-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On 27-Feb-2021, the patient experienced FATIGUE (tired) and PAIN IN EXTREMITY (arm hurt). On 28-Feb-2021, FATIGUE (tired) had resolved. On 01-Mar-2021, PAIN IN EXTREMITY (arm hurt) had resolved. Not Provided          Concomitant medication information was not reported. Treatment information as not reported. Action taken with mRNA-1273 (Moderna COVID-19 Vaccine) is considered as not applicable.   This case was linked to US-MODERNATX, INC.-MOD-2021-036914 (E2B Linked Report).   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 05-May-2021: Non-significant follow up appended.Reporter Contact info added; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-036914:Wife case
T106R given alcohol sponge bath; shrill, high pitched cry, unconsolable for 12hrs; Fever treated w/APAP; Gone in 24hrs; Phoned MD & hosp ER; 20FEB91 seen by MD;
Both arms that she received the vaccine in were swollen and red and were itching. Advised patient to call/visit MD ASAP and take some BENADRYL for now. (She said it was sore the day of and then had swelling and started itching on 10/25/11).
Patient woke up this morning with pain at injection site, "10x worse" than he felt after administration. Pain after injection but went away with 3 days.